Inhibition of cancer cell growth by internalized immuno-histone conjugates

Cancer Biotherapy and Radiopharmaceuticals

Volumn 11, Issue 1, 1996, Pages 77-86

  Rakowicz Szulczynska, Eva M ^a,b   McIntosh, David G ^a   Lewis, Paul ^c   Smith, McClure L ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c Analytical Biotechnology Services   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE; IODINE 125; MONOCLONAL ANTIBODY HISTONE COMPLEX; NICOTINE; UNCLASSIFIED DRUG;

ARTICLE; BREAST CANCER; CELL NUCLEUS; CONTROLLED STUDY; GROWTH INHIBITION; HUMAN; HUMAN CELL; PHAGOCYTOSIS; PRIORITY JOURNAL; RNA SYNTHESIS; TUMOR CELL LINE; UTERINE CERVIX CANCER;

EID: 0029922752     PISSN: 10849785     EISSN: None     Source Type: Journal    
DOI: 10.1089/cbr.1996.11.77     Document Type: Article

References (25)

1. Dosio F, Magnani P, Paganelli G, Samuel A, Chiesa G, Fazio F Three-step tumor pretargeting in lung cancer immunoscintigraphy. Journal of Nuclear Biol Med 1993,37:228.
2. Goldenberg DM. New imaging techniques in gastrointestinal cancer. Curr Opin Oncol 1993,5.697.
3. Griffiths GL, Goldenberg DM, Knapp FF Jr, Callahan AP, Chang CH, Hansen HJ Direct radiolabeling of monoclonal antibodies with generator-produced rhenium-188 for radioimmunotherapy: labeling and animal biodistribution. Cancer Research 1991; 51:4594
4. Blumenthal RD, Sharkey RM, Snyder D, Goldenberg DM. Reduction by anti-antibody administration of the radiotoxicity associated with 131 I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy. Journal National Cancer Institute 1989;81:194.
5. Welt S, Divgi CR, Kemeny N, Finn RD, Scott AM, Graham M, Germain JS, Richards EC, Larson SM, Oettgen HF, et al. Phase I/II study of iodine 131-labeled monclonal antibody A33 in patients with advanced colon cancer. Journal Clinical Oncology 1994,12:1561.
6. Welt S, Divgi CR, Scott AM, Garin-Chesa P, Finn RD, Graham M, Carswell EA, Cohen A., Larson SM, Old LJ, et al. Antibody targeting in metastatic colon cancer a phase I study of monoclonal antibody F19 against a cell-surface protein of reactive tumor stromal fibroblasts. Journal Clinical Oncology 1994;12:1193.
7. Meredith RF, Bueschen AJ, Khazaeli MB, Plott WE, Grizzle WE, Wheeler RH Schlom J, Russell CD, Liu T, LoBuglio AF. Treatment of metastatic prostate carcinoma with radiolabeled antibody CC49. Journal Nuclear Medicine 1994;35:1017.
8. Michalides R, Kwa B, Springall D, van-Zandwijk N, Koopman J, Hilkens J, Mooi W NCAM and lung cancer. Int Journal Cancer Suppl 1994; 8:34.
9. Camera L, Kinuya S, Garmestani K, Wu C, Brechbiel MW, Pai LH, McMurry TJ, Gansow OA, Pastan I, Paik CH, et al. Evaluation of the serum stability and in vivo biodistribution of CH-DPTA and other ligands for yttrium labeling of monoclonal antibodies. Journal of Nuclear Medicine 1994;35:882.
10. de-Bree R, Roos JC, uak JJ, den-Hollander W, van-den-Brekel MW, van-der-Wal JE, Tobi H, Snow GB, van-Dongen GA. Clinical imaging of head and neck cancer with technetium-99m-labeled monoclonal antibody E48 OgG or F(ab′)2 Journal Nuclear Medicine 1994;35:775.
11. Skolnick AA. First immunotoxin therapy for many common solid tumors enters phase I clinical trial (news). JAMA 1993;270:2280.
12. Lynch TJ Jr. Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer. Chest 1993;103:436S
13. Grossbard ML, Gribben JG, Freedman AS, Lambert JM, Kinsella J, Rabionowe SN, Eliseo L, Taylor JA, Blattler WA, Epstein CL, et al. Adjuvant immunotoxin therapy with anti-B-4-blocked ricin after autologous bone marrow transplantation for patients with B-cell non-Hodgkin's lymphoma. Blood 1993;81:2263.
14. Corliss J. Immunotoxin therapy: prospects for the future (news). Journal National Cancer Institute 1989;81:1862.
15. Vitetta ES, Krolick KA, Miyama-Inaba M, Cushley W, & Uhr JW. Immunotoxins. a new approach to cancer therapy. Science 1983,219:644.
16. Blakey DC and Thorpe PE. An overview of therapy with immunotoxins containing ricin or its A chain. Antibody, Immunoconj. Radiopharm 1988;1:1.
17. 2 fragment. Eur. J. Biochem 1980;104:381
18. Endo Y, Mitsui K, Matizuki M, and Tsurugi K. The mechanisms of action of ricin and related toxic lectins on eukaiyotic ribosomes. J Biol Chem 1987;202:5908.
19. Rakowicz-Szulczynska E, Otwiaski D, Rodeck U, and Koprowski H Epidermal growth factor (EGF) and monoclonal antibody to cell surface EGF receptor bind to the same chromatin receptor. Arch Biochem Biophys 1989;268:456.
20. Rakowicz-Szulczynska, E and Koprowski H. Nuclear uptake of monoclonal antibody to a surface glycoprotein and its effect on transcription. Arch Biochem Biophys 1989;271:366.
21. Rakowicz-Szulczynska E, Steplewski Z and Koprowski H. Nuclear translocation of monoclonal antibody directed against cell surface carbohydrate Y determinant. Am J Pathology 1992;141:937-947.
22. Rakowicz-Szulczynska EM. Nuclear antigens as the new targets in cancer therapy, in Nuclear Localization of Growth Factors and of Monoclonal Antibodies, E.M.Rakowicz-Szulczynska,ed., CRC Press, 1993.
23. Rakowicz-Szulczynska EM, Kaczmarski W, Raso V, Steimer KS, and Durda PJ Internalization of antigpl 20 monoclonal antibody and human antibodies by HIV-I-infected lymphocytes. Antibody Immunoconjugates, and Radiopharmaceuticals 1993;6:209-219.
24. Rakowicz-Szulczynska EM, McMosh DG and Smith ML. Growth factor-mediated mechanisms of nicotine-dependent carcinogenesis. Carcinogenesis 1994;15:1839-1846.
25. Grabarek Z and Gergely J. Zero-length crosslinking procedure with the use of active esters. Analytical Biochemistry 1990;185.131-135.